ResearcherWenzhou Medical UniversityNo recent work listed
Guogang Li
Matched on ORCID iD 0000-0003-0981-0328; OpenAlex author ID A5072707334. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers
Papers 5
- Downregulation of circ-STK39 suppresses pancreatic cancer progression by sponging mir-140-3p and regulating TRAM2-mediated epithelial-mesenchymal transition. Last author DOI 10.1007/s10495-023-01813-9↗
- Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Co-author DOI 10.1016/j.phymed.2023.154990↗
- Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
- Liquid biopsy in pancreatic cancer: the beginning of a new era. Co-author DOI 10.18632/oncotarget.24809↗
- [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chao Li · 1 shared paper, 2023 · strength 0.24
- Tingbo Liang · 3 shared papers, 2016–2019 · strength 0.23
- Paper Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Ca… DOI 10.1158/1535-7163.mct-17-1298↗
- Paper Liquid biopsy in pancreatic cancer: the beginning of a new era. DOI 10.18632/oncotarget.24809↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Chunmei Wen · 1 shared paper, 2023 · strength 0.18
- Jie Deng · 1 shared paper, 2023 · strength 0.18
- Qingqing Ruan · 1 shared paper, 2023 · strength 0.18
- Guihua Jin · 1 shared paper, 2023 · strength 0.18
- Yongheng Bai · 1 shared paper, 2023 · strength 0.18
- Tao Ma · 2 shared papers, 2018–2019 · strength 0.17
- Jianying Lou · 2 shared papers, 2016–2019 · strength 0.14
- Paper Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Ca… DOI 10.1158/1535-7163.mct-17-1298↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Risheng Que · 2 shared papers, 2016–2019 · strength 0.14
- Paper Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Ca… DOI 10.1158/1535-7163.mct-17-1298↗
- Paper [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
- Xueli Bai · 2 shared papers, 2016–2018 · strength 0.14
- Tao Wei · 1 shared paper, 2019 · strength 0.09
- Xiang Li · 1 shared paper, 2019 · strength 0.09
- Lei Zheng · 1 shared paper, 2019 · strength 0.09
- Xueli Bai · 1 shared paper, 2019 · strength 0.09
- Dipesh Kumar Yadav · 1 shared paper, 2018 · strength 0.09
- Wei Chen · 1 shared paper, 2018 · strength 0.09
- Qichun Wei · 1 shared paper, 2016 · strength 0.05
- Ri‐Sheng Yu · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.